NCT05238493View on ClinicalTrials.gov

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 26, 2022

Primary Completion Date

January 3, 2023

Study Completion Date

January 3, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

VEL-101

Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1

DRUG

Placebo

Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1

Trial Locations (1)

45212

CTI Clinical Research Center, Cincinnati

Sponsors
All Listed Sponsors
lead

Veloxis Pharmaceuticals

INDUSTRY

NCT05238493 - A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101 | Biotech Hunter | Biotech Hunter